This page is updated frequently with new Peptide-related patent applications.
|Foxc1 antibodies and methods of their use|
In one embodiment, an isolated antibody or functional fragment thereof which binds an antigenic peptide sequence of human foxc1 is provided herein. Such antibodies or functional fragments may be used to diagnose, prognose or treat basal-like breast cancer.
John Wayne Cancer Institute
|E1 enzyme mutants and uses thereof|
The invention provides isolated nucleic acids molecules, designated uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, which encode novel e1 enzyme variant proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing uba3, uae, or uba6, or other e1 enzyme variant nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a uba3, uae, or uba6, or other e1 enzyme variant gene has been introduced or disrupted.
Millennium Pharmaceuticals, Inc.
|Bardcoded protein array for multiplex single-molecule interaction profiling|
Methods for attaching barcodes to polypeptides are provided. Methods for detecting molecular interactions at the single molecule level are provided.
President And Fellows Of Harvard College
|Rhamnose promoter expression system|
The prokaryotic signal sequence is selected from signal peptides of periplasmatic binding proteins for sugars, amino acids, vitamins and ions. The expression of the nucleic acid sequence is controlled by the promoter region.
|Type ii restriction modification system methylation subunit of alicyclobacillus acidocaldarius|
Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from alicyclobacillus acidocaldarius are provided. Further provided are methods for modulating or altering recombination inside or outside of a cell using isolated and/or purified polypeptides and/or nucleic acid sequences from alicyclobacillus acidocaldarius..
Battelle Energy Alliance, Llc
|Novel methods, polypeptides and uses thereof|
The present invention provides methods for the production of recombinant polypeptides having serine protease activity, polypeptides obtainable by such methods and use of said polypeptides in medicine, cosmetics and industry. In particular, the invention provides recombinantly expressed mutants of trypsin i from atlantic cod, which mutants exhibit improved stability and/or catalytic properties relative to the wildtype trypsin purified from cod..
|Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease|
The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore
The present invention concerns a detergent and a pharmaceutical composition comprising a deoxyribonuclease (dnase), wherein the dnase is obtained from a fungal source. It further concerns a laundering method and the use of dnase.
|Stabilized single domain antibodies|
The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising vhhs in biological circulatory systems..
|Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof|
Disclosed herein are antibodies which specifically bind to at least one epitope defined by the immunogenic glycopeptide. Other aspects of the present disclosure are pharmaceutical composition comprising the antibody; and method for preventing and/or treating globo-h-positive cancer..
Mackay Medical Foundation The Presbyterian Church
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against krtcap3, fam26f, mgc52498, fam70a or tmem154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages.
Antibodies to hgf and compositions containing
The present invention is directed to antibodies and fragments thereof having binding specificity for hgf. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the vh, vl and cdr polypeptides described herein, and the polynucleotides encoding them.
Alderbio Holdings Llc
Fusion polypeptides have an fgfr2 polypeptide and cdnas encode such fusion polypeptides. Methods of diagnosing the presence of the fusion polypeptides or of a gene or rna sequence coding therefore in a sample from a subject as well as methods of treatment of a tumor instructed by the latter diagnosis..
Debiopharm International Sa
Constructs having a sirp-alpha domain or variant thereof
The present disclosure features signal-regulatory protein α (sirp-α) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory t-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The sirp-α constructs include a high affinity sirp-α d1 domain or variant thereof that binds cd47 with higher affinity than a wild-type sirp-α.
Alexo Therapeutics Inc.
Sperm-specific cation channel, and uses therefor
Nucleic acid and protein sequences relating to a cation channel which is sperm-specific (catsper1) are disclosed. The catsper1 protein is shown to be specifically expressed in sperm and to be necessary for sperm motility.
Children's Medical Center Corporation
Peptide agonists of glp-1 activity
Novel peptide agonists of glp-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the glp-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable.
Zealand Pharma A/s
Novel specific-binding polypeptides and uses thereof
The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of swiss prot q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of swiss prot q9npf7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of swiss prot q16552 and swiss prot q9npf7.
Pieris Pharmaceuticals Gmbh
Met e 1 tropomyosin variants for use in allergen-specific immunotherapy
The present invention provides isolated met e 1 polypeptides and nucleic acids encoding the isolated polypeptides that can prevent and/or alleviate an allergic response to shellfish tropomyosin. The polypeptides are based on the shrimp tropomyosin met e 1 protein and have been modified to act as hypoallergens.
The Regents Of The University Of California
Mutant fragments of ospa and methods and uses relating thereto
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein a (ospa), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a borrelia infection and a method of immunizing a subject.. .
Valneva Austria Gmbh
Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
Described herein is the generation of optimized h5n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h5n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on human and avian h5n1 isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
The invention relates to a method for inhibiting an adam protease, comprising inhibiting binding to an integrin-binding loop of a disintegrin domain in the adam protease. Also provided are cyclic peptides which inhibit binding to an integrin-binding loop of an adam protease, as well as associated pharmaceutical compositions, uses and methods of treatment..
Cancer Research Technology Limited
Modified apidaecin derivatives as antibiotic peptides
According to the invention, the object is attained in a first aspect by a peptide according to claim 1.. .
The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed..
Modified antimicrobial peptides
The present invention relates to modified antimicrobial peptides which incorporate a histidine tag, are conjugated with a fatty acid and/or are pegylated and their use in the treatment of microbial infections.. .
Neuroprotective composition and use
A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactically or as soon as possible post-injury in treating neuronal injury..
Wayne State University
Novel ruthenium complexes and their uses in processes for formation and/or hydrogenation of esters, amides and derivatives thereof
The present invention relates to novel ruthenium complexes and related borohydride complexes, and their use for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including preparing polyamides (e.g., polypeptides) by reacting dialcohols and diamines or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones), cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water to form carboxylic acids; and (10) dehydrogenation of beta-amino alcohols to form pyrazines. The present invention further relates to novel uses of certain pyridine ruthenium complexes..
Yeda Research And Development Co. Ltd.
Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
Herein is reported a method for producing a polypeptide in monomeric form comprising the following step: recovering the polypeptide in monomeric form from an ion exchange chromatography material by applying a solution comprising a non-ionic polymer and an additive.. .
Hoffmann-la Roche Inc.
Site specific protein modifications
The present invention relates to method and reagents for use in site-selective modification of protein and peptide. The site selective modification is a selective derivation of the amino functionality at the n-terminus of the protein or the polypeptide using the presence of a neighboring histidine amino acid to increase the reactivity of the n-terminal amino functionality.